Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Consensus Target Price of $20.50 According to Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has been given a consensus rating of “Hold” by the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.50.

A number of equities research analysts have recently weighed in on KROS shares. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, September 5th. Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th.

Insider Buying and Selling

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares in the company, valued at approximately $283,582.11. The trade was a 11.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 5,343 shares of company stock valued at $54,985. 12.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KROS. BlackRock Inc. bought a new stake in Keros Therapeutics during the second quarter worth $29,898,000. Nantahala Capital Management LLC acquired a new stake in shares of Keros Therapeutics in the 2nd quarter valued at $15,091,483. Dimensional Fund Advisors LP increased its stake in shares of Keros Therapeutics by 453.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after purchasing an additional 263,347 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Keros Therapeutics in the second quarter valued at about $2,641,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Keros Therapeutics by 40.2% in the first quarter. Y Intercept Hong Kong Ltd now owns 164,483 shares of the company’s stock worth $1,816,000 after acquiring an additional 47,122 shares during the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Trading Down 1.2%

Keros Therapeutics stock opened at $11.26 on Tuesday. The company has a market capitalization of $223.29 million, a price-to-earnings ratio of -3.04 and a beta of 1.12. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55. The stock’s 50 day moving average is $10.93 and its 200-day moving average is $11.04.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, equities research analysts predict that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Keros Therapeutics announced that its Board of Directors has initiated a share repurchase program on Wednesday, September 9th that permits the company to buyback $5.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 2.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing medicines that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. The company’s research is aimed at addressing diseases in which abnormal signaling affects blood-cell production, bone health, muscle function, or cardiovascular health.

Keros has developed investigational ligand-trap therapies designed to modify signaling by activin and related proteins.